Reimbursement 101: coding, coverage, payment
FDA clearance means you're allowed to sell your device. It says nothing about whether hospitals and physicians will get paid for using it, and if they don't get paid, they don't buy. Reimbursement is where more medtech commercialization plans die than anywhere else, largely because founders start thinking about it two years too late. The entire field hangs on a three-part framework.
1. Coding: does a billing code exist?
Providers bill using standardized codes: chiefly CPT codes for physician procedures, plus HCPCS codes for products and DRGs for inpatient stays. The first question for your device: can its use be billed under an existing code?
If yes, your path is dramatically easier. Your job becomes proving you fit that code and that your economics work within its payment. If no, you may need a new code, and that's a serious undertaking: the AMA CPT process typically runs 18-24 months, requires published clinical evidence and demonstrated use, and needs physician specialty society support. Temporary Category III codes exist for emerging technologies, but they usually carry no assigned payment.
2. Coverage: will payers pay for it?
A code without coverage is a number, not revenue. Coverage means a payer has decided your technology is medically necessary for defined indications. For Medicare, search the Medicare Coverage Database for national and local coverage determinations on technologies like yours. It's the fastest way to learn what evidence bar you're facing. Commercial payers make their own calls, typically informed by published randomized or comparative evidence, specialty society guidelines, and Medicare's lead.
The founder's mistake here is designing a pivotal trial that satisfies FDA but not payers. FDA asks "is it safe and effective?" Payers ask "is it better than what we already pay for, and for whom?" Those are different studies unless you plan them together.
3. Payment: is the amount enough?
Even with a code and coverage, the payment amount has to work, both for you and for the provider using your device. Look up actual Medicare rates in the Physician Fee Schedule and hospital payment systems. If your device makes a procedure more expensive without a payment mechanism that recognizes it, the economic story collapses no matter how good the clinical story is. For genuinely new inpatient technologies, mechanisms like NTAP can bridge the gap while you pursue permanent payment.
When to start: a timeline that works backward
- At concept stage: identify the codes used for the current standard of care in your indication; sketch who pays, how much, and who your economic buyer is.
- Before your pivotal trial: get payer feedback on endpoints (Early Payor Feedback); design the health-economic analysis into the study.
- During FDA review: if you'll need a new CPT code, begin specialty society conversations now. The 18-24 month clock plus evidence requirements means starting at clearance is starting late.
- At launch: arm your sales team with a reimbursement dossier: coding guidance, coverage summaries, and a hospital economic model.
Read next
CMS wrote its own plain-English walkthrough of this exact framework: the CMS Guide for Medical Technology Companies. Pair it with the reimbursement section of our resource library, and if your device qualifies for the Breakthrough Devices Program, know that breakthrough status increasingly carries reimbursement advantages worth understanding early.